Immune cell booster shows promise for Hard-to-Treat cancers
NCT ID NCT07274449
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new immune cell therapy (memory NK cells) combined with standard treatment for people with advanced solid tumors that have spread. The main goal is to check safety in a small group of 6 patients. If safe, more patients may be added to see if it helps shrink tumors or extend life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED / METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University
Nanjing, Jiangsu, 210008, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New cancer drug CFI-402257 enters first human trial
- New drug INV-6452 targets Hard-to-Treat breast cancers
- New mRNA vaccine takes on tough cancers
- Immune cell double punch takes on Hard-to-Treat tumors
- New cancer drug MBRC-101 enters human trials for Hard-to-Treat tumors
- New radioactive drug shows promise for Hard-to-Treat cancers